Open AccessCurrent trends in the treatment of HR+/HER2+ breast cancer
Author(s) -
Charlene Kay,
Carlos Martínez-Pérez,
James Meehan,
Mark Gray,
Victoria L. Webber,
J. Michael Dixon,
Arran Turnbull
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-0504
Subject(s) - medicine , palbociclib , neratinib , trastuzumab , oncology , trastuzumab emtansine , breast cancer , lapatinib , metastatic breast cancer , disease , pertuzumab , clinical trial , chemotherapy , cancer
Treatment for HR+/HER2+ patients has been debated, as some tumors within this luminal HER2+ subtype behave like luminal A cancers, whereas others behave like non-luminal HER2+ breast cancers. Recent research and clinical trials have revealed that a combination of hormone and targeted anti-HER2 approaches without chemotherapy provides long-term disease control for at least some HR+/HER2+ patients. Novel anti-HER2 therapies, including neratinib and trastuzumab emtansine, and new agents that are effective in HR+ cancers, including the next generation of oral selective estrogen receptor downregulators/degraders and CDK4/6 inhibitors such as palbociclib, are now being evaluated in combination. This review discusses current trials and results from previous studies that will provide the basis for current recommendations on how to treat newly diagnosed patients with HR+/HER2+ disease.